Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2015 by Nerviano Medical Sciences
Information provided by (Responsible Party):
Nerviano Medical Sciences Identifier:
First received: November 10, 2009
Last updated: May 25, 2015
Last verified: May 2015

The intent of the study is to assess the antitumor activity of PHA-848125AC as second-line treatment in patients with recurrent or metastatic, unresectable thymic carcinoma previously treated with chemotherapy.

Condition Intervention Phase
Thymic Carcinoma
Drug: Milciclib Maleate
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma Previously Treated With Chemotherapy

Further study details as provided by Nerviano Medical Sciences:

Primary Outcome Measures:
  • Progression-free survival rate at 3 months [ Time Frame: 3 months since treatment start ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Overall safety profile [ Time Frame: All cycles from enrollment to 28 days after last treatment ] [ Designated as safety issue: Yes ]
  • Assessment of additional measures of tumor control to further characterize the efficacy profile of PHA-848125AC [ Time Frame: Every 6 weeks during the entire study ] [ Designated as safety issue: No ]
  • Explorative baseline characterization of biomarkers in tumor tissue of consenting patients [ Time Frame: Baseline ] [ Designated as safety issue: No ]

Estimated Enrollment: 60
Study Start Date: November 2009
Estimated Study Completion Date: November 2015
Estimated Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Milciclib Maleate (PHA-848125AC)
100 and 50 mg Capsule 150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle
Drug: Milciclib Maleate

150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle.

Number of cycles: until disease progression or unacceptable toxicity.

Other Name: PHA-848125AC


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically proven diagnosis of unresectable B3 thymoma or thymic carcinoma recurrent or progressing after prior chemotherapy (only one prior systemic therapy allowed)
  • Presence of measurable disease
  • Age >=18 years
  • ECOG performance status 0-1
  • Negative pregnancy test (if female in reproductive years)
  • Use of effective contraceptive methods if men and women of child producing potential
  • Adequate liver function Total Serum Bilirubin <=1.5 x upper limit of normal (ULN) Transaminases (AST/ALT) <=2.5ULN (if liver metastases are present, then <=5ULN is allowed) ALP <=2.5ULN (if liver and/or bone metastases are present, then <=5ULN is allowed)
  • Adequate renal function Serum Creatinine <=ULN or Creatinine Clearance calculated by Cockcroft and Gault's formula > 60 mL/min.
  • Adequate hematologic status ANC >=1,500cells/mm3 Platelet Count >=100,000cells/mm3 Hemoglobin >=9.0g/dL
  • Two weeks must have elapsed since completion of prior chemotherapy, minor surgery, radiotherapy (provided that no more than 25% of bone marrow reserve has been irradiated)
  • Resolution of all acute toxic effects of any prior treatments to NCI CTC (Version 3.0) grade <=1

Exclusion Criteria:

  • Any of the following in the past 6 months: myocardial infarction, uncontrolled cardiac arrhythmia, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis
  • Grade >1 retinopathy
  • Known brain metastases
  • Known active infections
  • Pregnant or breast feeding women
  • Diabetes mellitus uncontrolled
  • Gastrointestinal disease that would impact on drug absorption
  • Patients under treatment with anticoagulants or with coagulation disorders or with signs of hemorrhage at baseline
  • Patients with previous history or current presence of neurological disorders, including epilepsy (although controlled by anticonvulsant therapy), Parkinson's disease and extra-pyramidal syndromes
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that make the patient inappropriate for entry into this study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01011439

United States, Arizona
TGen Clinical Research Services at Scottsdale Healthcare Active, not recruiting
Scottsdale, Arizona, United States, 85258
United States, Maryland
NIH, Center for Cancer Research, Medical Oncology Active, not recruiting
Bethesda, Maryland, United States, 20892
Hopital Larrey Recruiting
Toulouse Cedex, France, 31059
Contact: Julien Mazières, MD    +33 05 67 77 18 37   
Principal Investigator: Julien Mazières, MD         
Institut de cancerologie Gustave Roussy Recruiting
Villejuif Cedex, France, 94805
Contact: Benjamin Besse, MD PhD    +33 142114322   
Principal Investigator: Benjamin Besse, MD PhD         
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Recruiting
Milano, (mi), Italy, 20133
Contact: Marina C. Garassino, MD    +39 0223903813   
Principal Investigator: Marina C. Garassino, MD         
Azienda Ospedaliera San Luigi Gonzaga Recruiting
Orbassano, Italy, 10043
Contact: Silvia Novello, MD    +39 011 9026978   
Principal Investigator: Silvia Novello, MD         
Sponsors and Collaborators
Nerviano Medical Sciences
Study Director: Anna Petroccione, MD CLIOSS (Nerviano Medical Sciences Group), Italy
Principal Investigator: Glen Weiss, MD Scottsdale Clinical Research Institute, USA
Principal Investigator: Benjamin Besse, MD Institut Gustave Roussy, Villejuif, France
Principal Investigator: Julien Mazières, MD Hopital Larrey CHU, Toulouse, France
Principal Investigator: Silvia Novello, MD Ospedale San Luigi Gonzaga, Orbassano, Italy
Principal Investigator: Arun Rajan, MD. National Cancer Institute (NCI)
Principal Investigator: Marina Chiara Garassino, MD Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
  More Information

No publications provided

Responsible Party: Nerviano Medical Sciences Identifier: NCT01011439     History of Changes
Other Study ID Numbers: CDKO-125a-006, 2009-014338-79
Study First Received: November 10, 2009
Last Updated: May 25, 2015
Health Authority: United States: Food and Drug Administration
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Italy: AIFA - The Italian Medicines Agency

Keywords provided by Nerviano Medical Sciences:
B3 and C malignant thymoma

Additional relevant MeSH terms:
Lymphatic Diseases
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Complex and Mixed
Neoplasms, Glandular and Epithelial
Thoracic Neoplasms
Thymus Neoplasms processed this record on August 27, 2015